0.3431

8.99% -0.0339

After Hours: .35 0.0069 +2.01%

Transcode Therapeutics Inc (RNAZ)

Overview News Price History Financials Why RNAZ Down? Discussions Forecast Stock Split

Transcode Therapeutics Inc stock is traded at $0.3431, with a volume of 646.02K. It is down -8.99% in the last 24 hours and down -41.60% over the past month. TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Previous Close:

$0.377

Open:

$0.374

24h Volume:

646.02K

Relative Volume:

0.39

Market Cap:

$5.96M

Revenue:

Net Income/Loss:

$-19.59M

P/E Ratio:

-0.0141

EPS:

-24.29

Net Cash Flow:

$-16.49M

1W Performance:

+2.05%

1M Performance:

-41.60%

6M Performance:

-80.83%

1Y Performance:

-96.32%

1-Day Range:

$0.3318

$0.38

1-Week Range:

$0.33

$0.4586

52-Week Range:

$0.216

$18.66

Transcode Therapeutics Inc Stock (RNAZ) Company Profile

Name

Transcode Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

857-301-6857

Address

6 LIBERTY SQUARE, BOSTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

RNAZ's Discussions on Twitter

Compare RNAZ with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNAZ Transcode Therapeutics Inc	0.3431	5.96M	0	-19.59M	-16.49M	-24.29
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Transcode Therapeutics Inc Stock (RNAZ) Latest News

Nov 27, 2024

TransCode Therapeutics announces $8M private offering - MSN

Nov 27, 2024

CMG Announces Appointment of Herman Nieuwoudt as President, Bluware - The Manila Times

Nov 27, 2024

TransCode secures $8 million in private placement By Investing.com - Investing.com UK

Nov 27, 2024

TransCode Therapeutics Secures $8M Private Placement, Issues 21.2M Shares | RNAZ Stock News - StockTitan

Nov 27, 2024

Nov 26, 2024

Transcode Therapeutics announces 1-for-33 reverse stock split - Yahoo Finance

Nov 26, 2024

TransCode Therapeutics approves reverse stock split By Investing.com - Investing.com South Africa

Nov 26, 2024

Nov 25, 2024

TransCode Therapeutics advances with stockholder approvals By Investing.com - Investing.com UK

Nov 25, 2024

TransCode Therapeutics approves reverse stock split - Investing.com

Nov 25, 2024

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Maintain Nasdaq Listing | RNAZ Stock News - StockTitan

Nov 25, 2024

Nov 19, 2024

Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World

Nov 19, 2024

Craig Hallum Downgrades Sow Good (NASDAQ:SOWG) to Hold - Defense World

Nov 19, 2024

TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Defense World

Nov 19, 2024

The Goldman Sachs Group Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $41.00 - Defense World

Nov 19, 2024

TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 19, 2024

Sow Good (NASDAQ:SOWG) Lowered to Neutral Rating by Roth Mkm - Defense World

Nov 19, 2024

Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World

Nov 19, 2024

Shoals Technologies Group (NASDAQ:SHLS) Price Target Lowered to $7.00 at Morgan Stanley - Defense World

Nov 19, 2024

Nov 15, 2024